Vir Biotechnology, Inc. (VIR)

NMS – Цена в реальном времени. Валюта: USD

8.96

+0.03 (0.34%)

При закрытии: Aug 12, 2026, 4:00 PM EDT

9.05

+0.09 (1.00%)

После закрытия: Aug 12, 2026, 4:40 PM EDT

06.08.2026

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

06.08.2026

Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology NASDAQ: VIR reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs, highlighting completed enrollment in a key hepatitis delta study, plans for multiple data readouts, and expanded development activity for its prostate cancer candidate VIR-5500.

06.08.2026

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Vir Biotechnology, Inc. (VIR) came out with quarterly earnings of $0.47 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to a loss of $0.8 per share a year ago.

05.08.2026

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2026. “This is a pivotal time for the CHD community, when availability of new therapies could improve awareness, testing and access to care. At EASL, experts emphasized that achieving durable suppression of hepatitis delta virus to undetectable levels is a key predictor of improved clinical outcomes for people with CHD. Our.

Видео

No Data

There is no data to display

Пресс-релизы

05.08.2026

Vir Biotechnology, Inc. (VIR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Vir Biotechnology, Inc. (VIR)

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Видео

No Data

Пресс-релизы

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Видео

No Data

Пресс-релизы

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Search stocks

Vir Biotechnology, Inc. (VIR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Vir Biotechnology, Inc. (VIR)

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Видео

No Data

Пресс-релизы

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

Vir Biotechnology Q2 Earnings Call Highlights

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Видео

No Data

Пресс-релизы

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results